Summit Therapeutics' partner Akeso announced positive topline results from its Phase III HARMONi-GI1 study for ivonescimab in advanced biliary tract cancer, meeting primary and key secondary endpoints. This significant clinical trial success for a key pipeline asset could substantially boost Summit's future revenue potential and market valuation.
Summit Therapeutics announced that its partner, Akeso Inc., reported positive topline results from the Phase III HARMONi-GI1 study for ivonescimab in advanced biliary tract cancer. The study achieved statistically significant and clinically meaningful superiority in overall survival (OS), and also met key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR). This is a major positive development for Summit as ivonescimab is a critical part of their pipeline, licensed from Akeso for development and commercialization outside of China. The success of this trial significantly de-risks the drug and opens up a new potential market, offering a strong long-term growth opportunity for Summit and likely leading to a positive short-term stock reaction.